Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

Dig Liver Dis. 2007 Mar;39(3):253-6. doi: 10.1016/j.dld.2006.11.012. Epub 2007 Feb 1.

Abstract

Introduction: Induction therapy has been recently adopted for intestinal transplant.

Patients and methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax) or Alemtuzumab (Campath-1H).

Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection.

Discussion and conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Daclizumab
  • Female
  • Graft Rejection / prevention & control*
  • Graft Survival
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Intestines / transplantation*
  • Male
  • Postoperative Period
  • Transplantation, Homologous
  • Viscera / transplantation*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Alemtuzumab
  • Daclizumab